On 31 July 2018, orphan designation (EU/3/18/2053) was granted by the European Commission to Lakeside Regulatory Consulting Services Ltd, United Kingdom, for tamibarotene for the treatment of acute myeloid leukaemia.
|Disease / condition||
Treatment of acute myeloid leukaemia
|Date of decision||
|Orphan decision number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see: